🧠Oruen CNS Weekly Roundup: The Latest in CNS Medicine 🧠Â
The CNS field continues to evolve rapidly, with new developments emerging across psychiatry, neurology, and interventional neuroscience. This week’s roundup highlights key updates across multiple therapeutic areas.
Depression
Kv7 channel modulator shows promise for anhedonia in MDD
HCPLive reports that azetukalner, a Kv7 potassium channel opener, showed encouraging secondary and exploratory signals in major depressive disorder with anhedonia at ADAA 2026, despite the primary endpoints being nonsignificant. The piece is notable because it points to a mechanistically different approach in depression, with a specific focus on reward-related symptoms.
Continue reading here: https://www.hcplive.com/view/kv7-channel-modulator-shows-promise-anhedonia-mdd-james-murrough-md
ADHD / Sleep Disorders
MHRA approves melatonin for children with ADHD and sleep onset insomnia
NeurologyLive reports that the UK MHRA has approved a melatonin oral solution for children and adolescents aged 6 to 17 years with ADHD and sleep onset insomnia. The linked trial data showed improvements in sleep duration, sleep latency, and sleep efficiency, making this a practical update at the overlap of ADHD and sleep medicine.
Continue reading here: https://www.neurologylive.com/view/melatonin-treatment-approved-mhra-children-with-adhd-sleep-onset-insomnia
Alzheimer’s disease
Older adults show high willingness for Alzheimer’s blood tests
A new News-Medical report on Northwestern survey data suggests that most older adults would be willing to undergo biomarker blood testing for Alzheimer’s risk. The story matters because blood-based testing is increasingly seen as a more accessible alternative to scans and spinal taps, especially in primary care settings where early memory concerns first present.
Continue reading here: https://www.news-medical.net/news/20260415/Older-adults-show-high-willingness-for-Alzheimere28099s-blood-tests.aspx
Headache / Migraine
Epilepsy gene implicated in severe migraine disorder
Medical Xpress reports that mutations in SCN2A, previously linked to epilepsy and neurodevelopmental disorders, may also cause familial and sporadic hemiplegic migraine. The finding broadens the genetic landscape of severe migraine and strengthens the mechanistic link between migraine and other neuronal channelopathies.
Continue reading here: https://medicalxpress.com/news/2026-04-epilepsy-gene-implicated-severe-migraine.html
Movement Disorders
FDA clears Cala kIQ Plus for tremor in essential tremor and Parkinson disease
NeurologyLive reports FDA clearance of the updated Cala kIQ Plus wearable transcutaneous afferent patterned stimulation system for temporary relief of action hand tremor in essential tremor and postural/kinetic tremor symptoms in Parkinson disease. The update adds adaptive features and reinforces the growing role of wearable neuromodulation in movement disorders.
Continue reading here: https://www.neurologylive.com/view/fda-clears-cala-kiq-plus-essential-tremor-parkinson-disease-hand-tremor
Stroke
Key takeaways from the 2026 stroke guidelines
NeurologyLive’s guideline discussion highlights the shift toward tenecteplase, greater use of multimodal imaging, and new attention to pediatric stroke care in the updated 2026 acute ischemic stroke recommendations. It is a useful practice-focused update because it centers on how the new guidance may change patient selection and treatment decisions in routine care.
Continue reading here: https://www.neurologylive.com/view/key-takeaways-2026-stroke-guidelines
Neuro-oncology
Can AI chatbots help brain tumor patients understand their care?
News-Medical covers emerging evidence that AI tools may help brain tumor patients access and interpret complex care information, while also warning about the risks of inaccurate or poorly supervised outputs. The article is especially relevant as patient-facing AI becomes more common in oncology communication.
Continue reading here: https://www.news-medical.net/news/20260326/Can-AI-chatbots-help-brain-tumor-patients-understand-their-care.aspx
Pain
Researchers use light-activated drugs to map the brain’s internal painkillers
A new News-Medical report describes work using a light-activated naloxone tool to show that both morphine-induced and placebo pain relief rely on opioid signaling in the vlPAG brain region. The study stands out because it offers a highly targeted way to investigate endogenous pain control and could inform future chronic pain strategies.
Continue reading here: https://www.news-medical.net/news/20260417/Researchers-use-light-activated-drugs-to-map-the-brains-internal-painkillers.aspx